186 related articles for article (PubMed ID: 35704797)
21. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
Abdulrahman RM; Verloop H; Hoftijzer H; Verburg E; Hovens GC; Corssmit EP; Reiners C; Gelderblom H; Pereira AM; Kapiteijn E; Romijn JA; Visser TJ; Smit JW
J Clin Endocrinol Metab; 2010 Aug; 95(8):3758-62. PubMed ID: 20484486
[TBL] [Abstract][Full Text] [Related]
24. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans.
Maia AL; Kim BW; Huang SA; Harney JW; Larsen PR
J Clin Invest; 2005 Sep; 115(9):2524-33. PubMed ID: 16127464
[TBL] [Abstract][Full Text] [Related]
25. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A; Gambale C; Cappagli V; Bottici V; Rossi P; Caciagli M; Papini P; Taddei D; Ortori S; Gabbrielli L; Celi A; Materazzi G; Elisei R; Matrone A
Eur J Endocrinol; 2022 Dec; 187(6):905-915. PubMed ID: 36314655
[TBL] [Abstract][Full Text] [Related]
26. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
27. Presence and regulation of D1 and D2 deiodinases in rat white adipose tissue.
Calvo RM; Obregon MJ
Metabolism; 2011 Sep; 60(9):1207-10. PubMed ID: 21397282
[TBL] [Abstract][Full Text] [Related]
28. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
29. Sodium selenite supplementation does not fully restore oxidative stress-induced deiodinase dysfunction: Implications for the nonthyroidal illness syndrome.
Wajner SM; Rohenkohl HC; Serrano T; Maia AL
Redox Biol; 2015 Dec; 6():436-445. PubMed ID: 26402162
[TBL] [Abstract][Full Text] [Related]
30. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat.
Bates JM; St Germain DL; Galton VA
Endocrinology; 1999 Feb; 140(2):844-51. PubMed ID: 9927314
[TBL] [Abstract][Full Text] [Related]
31. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.
Castagna MG; Dentice M; Cantara S; Ambrosio R; Maino F; Porcelli T; Marzocchi C; Garbi C; Pacini F; Salvatore D
J Clin Endocrinol Metab; 2017 May; 102(5):1623-1630. PubMed ID: 28324063
[TBL] [Abstract][Full Text] [Related]
32. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
33. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Subbiah V; Gouda MA; Iorgulescu JB; Dadu R; Patel K; Sherman S; Cabanillas M; Hu M; Castellanos LE; Amini B; Meric-Bernstam F; Shen T; Wu J
NPJ Precis Oncol; 2024 Mar; 8(1):62. PubMed ID: 38438731
[TBL] [Abstract][Full Text] [Related]
34. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse.
Zavacki AM; Ying H; Christoffolete MA; Aerts G; So E; Harney JW; Cheng SY; Larsen PR; Bianco AC
Endocrinology; 2005 Mar; 146(3):1568-75. PubMed ID: 15591136
[TBL] [Abstract][Full Text] [Related]
35. Scope and limitations of iodothyronine deiodinases in hypothyroidism.
Gereben B; McAninch EA; Ribeiro MO; Bianco AC
Nat Rev Endocrinol; 2015 Nov; 11(11):642-652. PubMed ID: 26416219
[TBL] [Abstract][Full Text] [Related]
36. Life without the iodothyronine deiodinases.
Galton VA; de Waard E; Parlow AF; St Germain DL; Hernandez A
Endocrinology; 2014 Oct; 155(10):4081-7. PubMed ID: 24949664
[TBL] [Abstract][Full Text] [Related]
37. A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A; Bastard K; Wang B; Gild M; Luxford C; Gill A; Robinson B; Bullock M; Clifton-Bligh R
Thyroid; 2023 Jan; 33(1):119-125. PubMed ID: 36416226
[No Abstract] [Full Text] [Related]
38. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
40. Hypothyroidism induces type I iodothyronine deiodinase expression in tilapia liver.
Van der Geyten S; Toguyeni A; Baroiller JF; Fauconneau B; Fostier A; Sanders JP; Visser TJ; Kühn ER; Darras VM
Gen Comp Endocrinol; 2001 Dec; 124(3):333-42. PubMed ID: 11742517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
